Andrew Technologies to Feature Two Powerful New Studies at IFATS San Diego 2016

TUSTIN, Calif.–(BUSINESS WIRE)–Andrew Technologies, LLC today announced that it will feature two
presentations at the International Federation for Adipose Therapeutics
and Science, IFATS San Diego 2016 conference. The IFATS conference is
“the premier meeting dedicated to the science of fat grafting,” bringing
together clinical practitioners of stem cell treatment and fat grafting,
and stem cell researchers from a variety of specialties.

Spencer A. Brown, PhD, Director of Surgical Research at Cooper
University in Camden, NJ, will present his latest results on the
characterization of HydraSolve lipoaspirate (fat) during the Industry
Showcase Thursday November 17th, 5:00 p.m. to 6:30 p.m. His
presentation will highlight these key findings:

  • HydraSolve fat demonstrates high viability levels, possibly 8% to 10%
    more viable than fat harvested with other methods.
  • Stromal Vascular Fraction (SVF) from HydraSolve fat contains high
    levels of isolated adipose-derived stem cells that differentiated into
    additional fat cells (adipocyte), cartilage cells (chondrocytes) and
    bone cells (osteoblasts) when cultured. Adipose tissue is one of the
    most readily available sources of adult mesenchymal stem cells for
    regenerative cell therapy.

Dr. Brown explained, “It is exciting to see the high cell viability of
HydraSolve fat lipoaspirates in our initial laboratory characterizations
compared to other methods, as well as the high quantity and
differentiation of adipose derived stem cells, which are promising cells
for clinical regenerative therapies.”

Christopher P. Godek, MD, Medical Director of Personal
Enhancement Center in Toms River, N.J., will present the paper,
“Autologous Fat Transfer Utilizing Tissue Liquefaction Technology:
Safety, Efficacy and Long-Term Results” during the Plenary Session on
Saturday November 19 at 9:50 a.m.

Dr. Godek and his colleagues harvested fat with TLT, then transferred
the fat into multiple host sites including breast reconstruction.

“We found the TLT method of fat harvest to be safe and effective.
Long-term survival of the graft was excellent, with patients retaining
70% or more of the transferred fat and favorable improvements apparent
in both the donor and recipient sites,” Dr. Godek said. “The technology
allows us to perform autologous fat transfer atraumatically to maintain
adipocyte viability and optimize long-term fat survival.”

“These findings are important to clinicians working in fat grafting,
reconstructive and regenerative medicine. The gentle and efficient,
high-volume harvesting of clean, high quality fat tissue, full of
viable, differentiating stem cells should place HydraSolve with TLT at
the head of the class,” commented Dr. Mark S. Andrew, Founder and Chief
Scientific Officer of Andrew Technologies. “We look forward to sharing
these exciting developments with opinion leaders from around the world
at IFATS San Diego 2016.”

Attendees are also invited to visit Andrew Technologies at booth #3 at
IFATS San Diego 2016 to learn more about HydraSolve with TLT.

About HydraSolve

HydraSolve is a novel liposuction device based on the proprietary
surgical innovation, Tissue Liquefaction Technology™ (TLT), which
combines natural saline solution with low levels of temperature and
pressure to liquefy only targeted fat tissue. Because fat tissue is
liquefied, the cutting of fat by forceful thrusts of the cannula is no
longer required. HydraSolve is the first liposuction device
FDA cleared for autologous fat transfer. The device is primarily used to
transfer fat for breast reconstruction following breast cancer treatment
and is not intended for treatment of obesity. Fat transfer and
liposuction are surgical procedures that have risks similar to other
cosmetic surgeries. For more information, please go to www.hydrasolve.com.

About Andrew Technologies, LLC

Andrew Technologies, LLC, is a privately funded medical technology
company committed to improving patients’ lives through precision
surgery. Founded in 2007, Andrew received FDA clearance for HydraSolve
in 2012. HydraSolve is primarily used to transfer fat for breast
reconstruction following breast cancer treatment. In addition to
HydraSolve, Andrew has an impressive research pipeline that includes
minimally invasive surgery to correct type 2 diabetes and adipose stem
cell isolation.

Contacts

Pascale Communications
Amy Phillips, 412-327-9499
amy@pascalecommunications.com